Market Research Report
Global Nephrology Drugs Market - 2022-2029
|Global Nephrology Drugs Market - 2022-2029|
Published: May 7, 2022
Content info: 180 Pages
Delivery time: 2 business days
The global nephrology drugs market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).
The nephron is a significant component of the kidney that is responsible for blood filtration. Both diabetes and hypertension impair nephron function and can harm them. Additionally, this has an impact on the filtration rate of nephrons. Nephrology medicines treat chronic kidney problems such as kidney stones, kidney failure, and kidney cancer. The kidney's function steadily deteriorates as a result of such illnesses. Drugs used in the therapy of nephrology include Invokana, Phoslo, Renvela, Sensipar, and Procrit.
The growth of nephrology drugs is fueled by factors such as an increase in kidney failure cases, an increase in unhealthy lifestyle adaptation, an increase in the prevalence of chronic nephrology diseases, an increase in the geriatric population, an increase in demand for diagnostic tests, an increase in excessive alcohol consumption, and an increase in the obese population.
Product approvals and launches are expected to drive market growth over the forecast period.
Key market players focus on novel product launches and approvals to expand their product portfolio and strengthen their global market presence.For instance in April 2021, Farxiga is approved in the United States for the treatment of chronic kidney disease in patients with and without type 2 diabetes who are at risk of progression. In April 2020, GSK has received the first regulatory approval for Duvroq (daprodustat) in Japan to treat anemia caused by chronic kidney disease. In August 2017, Amgen, Inc. has received approval from the European Commission (EC) to expand the use of Mimpara (cinacalcet) for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older who are on dialysis and whose secondary HPT is not adequately controlled with the standard of care therapy.
Furthermore, Amgen, Inc. received FDA approval in February 2017 for its Parsabiv (etelcalcetide) indicated for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Furthermore,the rising incidences of renal diseases eventually lead to the development of chronic kidney disease. According to a 2019 report published by the Centers for Disease Control and Prevention, chronic kidney disease affects approximately 15% of adults in the United States, or approximately 37 million people (CKD). According to current estimates, 9 out of every 10 people with chronic kidney disease are not diagnosed with the disease. Furthermore, current estimates show that chronic kidney disease is higher among the older population, i.e., people aged 65 years or older, with a 38 percent prevalence. The incidence of this disorder is expected to be 13% in adults aged 45 to 64 years and 7% in adults aged 18 to 44 years. Furthermore, the report states that chronic kidney disease affects women more than men, with a 15% and a 12% prevalence rate, respectively. Furthermore, government initiatives to promote research activities and raise public awareness about the disorder are expected to result in a growing supply of improved drugs on the market.This contributes to the growth of the global nephrology drugs market.
Lack of awareness about kidney disorders is likely to hamper the market growth
The main factor expected to limit the growth of the nephrology drugs market is a lack of awareness about kidney disorders. Despite government efforts to raise awareness about chronic kidney disease (CKD) through the distribution of clinical practice guidelines and recommendations for patients with chronic kidney disease or its risk factors, community awareness events such as World Kidney Day, and free screening efforts for high-risk individuals such as the Kidney Early Evaluation Program (KEEP), chronic kidney disease awareness remains unacceptably low. For example, in March 2018, a cross-sectional study for chronic kidney disease evaluation was published in BMC Public Health, revealing that people in Australia have a very poor understanding of chronic kidney disease (CKD), with only half of participants knowing that medications can help to slow the progression of chronic kidney disease. Furthermore, only 23.4 percent of total chronic kidney disease participants knew that herbal supplements are ineffective in treating chronic kidney disease.
COVID-19 Impact Analysis
COVID-19 has caused a widespread disturbance in healthcare workflows around the world. Various industries, including several sub-domains of healthcare, have been forced to close their doors because of the sickness temporarily. The overall impact of the COVID-19 pandemic on key participants in the nephrology medicines market remained negative. The COVID-19 epidemic has put a strain on the global healthcare system. COVID-19 has led nephrology drug clinical trials to be delayed, as well as poor usage of these treatments. Production has been halted due to widespread lockdowns, causing supply chain challenges. During this time, the COVID-19 pandemic has been a major impediment to the progress of nephrology therapeutic trials. The coronavirus outbreak is causing havoc in clinical trials worldwide, affecting the management of present trials and the planning of future trials. Market competitors and research institutions, on the other hand, are focusing on starting clinical trials related to COVID-19 to understand better the impact of chronic renal disease therapy medications on COVID-19 patients. As a result, the COVID-19 pandemic is predicted to impact the worldwide next-generation sequencing informatics market's growth substantially.
The ACE inhibitors segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Angiotensin-converting enzyme (ACE) inhibitors reduce blood pressure by relaxing the veins and arteries. Angiotensin-converting enzyme inhibitors (ACE inhibitors) stop the body from manufacturing angiotensin II, a chemical that narrows blood arteries. High blood pressure can result from this constriction, making the heart work harder. Angiotensin II also produces blood pressure-raising hormones.The ACE inhibitors segment currently dominates the global nephrology drugs market by drug class, and this is expected to continue during the forecast period due to an increase in the prevalence of various cardiovascular and hypertension conditions, as well as changing lifestyles. Cardiovascular diseases are the ruling cause of death throughout the world.
In 2019, an estimated 17.9 million people died from CVDs, accounting for 32% of global deaths. A heart attack or a stroke caused Eighty-five percent of these deaths.More than three-quarters of CVD deaths occur in low- and middle-income countries.Cardiovascular diseases were responsible for 38 percent of the 17 million premature deaths (under the age of 70) caused by noncommunicable diseases in 2019.(Source:World Health Organiation). ACE inhibitors are used to prevent and cure kidney disease (nephropathy) in people suffering from hypertension or diabetes.
North America region holds the largest market share of global nephrology drugs market
North America accounted for the biggest market share in 2020 due to rising obesity rate and the increasing prevalence of diabetic patients are two major factors influencing the nephrology drugs market in the United States. Increased funding from government agencies and healthcare organizations played a significant role in propelling the nephrology drug market.
According to the Centers for Disease Control and Prevention, more than 20 million people in the United States are diagnosed with chronic kidney disease each year. Europe remained the second-largest market for nephrology drugs in terms of revenue. The high prevalence of chronic kidney disease was the primary driver in Europe. During the forecast period of 2021 to 2029, Asia Pacific had the highest growth rate. Rising incidence of diabetes and cardiovascular disorders, emerging healthcare infrastructure and regulations, increased population, increased development, per capita income and healthcare spending, increased government initiatives, and increased public awareness are the key drivers in the Asia Pacific.
The nephrology drugs market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Astra Zeneca, Amgen Inc, Pfizer, Fierce Pharma, Teva Pharmaceutical, Akebia Therapeutics inc, Johnson & Johnson , Roche, Nexus Lifecare .The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the nephrology drugs market globally. For instance In November 2017, The FDA has approved SUTENT® (sunitinib malate) by Pfizer as the first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma.
Overview: Nexus Lifecare Pvt. Ltd., which began operations in 2007, is one of the leading Manufacturers, Suppliers, Wholesalers, Traders, and Retailers of a wide range of Injectable Drugs and Cancer Medicine. Oncology Medicine, Anti Cancer Injection, Nephrology Medicine, and many other products are available.
Ketosteril tablets : Ketosteril Tablets, also known as Compound Ketosteril Tablets, prevent and treat renal damage caused by protein metabolism disorders in chronic kidney disease (CKD). Low-protein diets enhance the effects.
Visualize the composition of the Global Nephrology Drugs market segmentation by Drug class, route of administration, distribution channel, and region highlighting the key commercial assets and players.
Identify commercial opportunities in Global Nephrology Drugs market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of Global Nephrology Drugs market- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The Global Nephrology Drugs market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
LIST NOT EXHAUSTIVE